- Home
- LXFR vs TRVI Comparison
LXFR vs TRVI Comparison
Compare LXFR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXFR
- TRVI
- Stock Information
- Founded
- LXFR 1898
- TRVI 2011
- Country
- LXFR United States
- TRVI United States
- Employees
- LXFR N/A
- TRVI N/A
- Industry
- LXFR Major Chemicals
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- LXFR Industrials
- TRVI Health Care
- Exchange
- LXFR Nasdaq
- TRVI Nasdaq
- Market Cap
- LXFR 380.9M
- TRVI 383.4M
- IPO Year
- LXFR 2012
- TRVI 2019
- Fundamental
- Price
- LXFR $12.03
- TRVI $6.29
- Analyst Decision
- LXFR
- TRVI Strong Buy
- Analyst Count
- LXFR 0
- TRVI 8
- Target Price
- LXFR N/A
- TRVI $15.94
- AVG Volume (30 Days)
- LXFR 169.0K
- TRVI 4.1M
- Earning Date
- LXFR 04-29-2025
- TRVI 05-06-2025
- Dividend Yield
- LXFR 4.29%
- TRVI N/A
- EPS Growth
- LXFR N/A
- TRVI N/A
- EPS
- LXFR 0.68
- TRVI N/A
- Revenue
- LXFR $391,900,000.00
- TRVI N/A
- Revenue This Year
- LXFR $2.26
- TRVI N/A
- Revenue Next Year
- LXFR $5.85
- TRVI N/A
- P/E Ratio
- LXFR $17.84
- TRVI N/A
- Revenue Growth
- LXFR N/A
- TRVI N/A
- 52 Week Low
- LXFR $9.26
- TRVI $2.30
- 52 Week High
- LXFR $15.64
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- LXFR 35.81
- TRVI 78.13
- Support Level
- LXFR $11.86
- TRVI $4.24
- Resistance Level
- LXFR $12.62
- TRVI $7.39
- Average True Range (ATR)
- LXFR 0.64
- TRVI 0.50
- MACD
- LXFR -0.07
- TRVI 0.21
- Stochastic Oscillator
- LXFR 25.16
- TRVI 66.67
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.